70914 Federal Register / Vol. 65, No. 229 / Tuesday, November 28, 2000 / Notices

Property and Administrative Services

Act of 1949, 40 U.S.C. 484(j)(2)).

2. Donation of surplus personal

property for use in any State for

purposes of education, public health, or

civil defense, or for research for any

such purposes (section 203(j) (3) and (4)

of the Federal Property and

Administrative Services Act of 1949, 40

U.S.C. 484(j) (3) and (4)), and the

making available to State agencies for

surplus property, or the transfer of title

to such agencies, of surplus personal

property approved for donation for

purposes of education, public health, or

civil defense, or for research for any

such purposes (section 203(n) of the

Federal Property and Administrative

Services Act of 1949, 40 U.S.C. 484(n)).

3. Disposal of surplus real and related

personal property for purposes of

education or public health, including

research (section 203(k)(1) of the

Federal Property and Administrative

Services Act of 1949, 40 U.S.C.

484(k)(1)).

4. Donation of property for public

airport purposes (section 13(g) of the

Surplus Property Act of 1944, 50 U.S.C.

App. 1622(g); section 23 of the Airport

and Airway Development Act of 1970,

Public Law 91–258).

5. Disposal of surplus real property,

including improvements, for use as a

historic monument (section 13(h) of the

Surplus Property Act of 1944, 50 U.S.C.

App. 1622(h)).

6. Disposal of surplus real and related

personal property for public park or

public recreational purposes (section

203(k)(2) of the Federal Property and

Administrative Services Act of 1949, 40

U.S.C. 484(k)(2).

7. Disposal of real property to States

for wildlife conservation purposes (Act

of May 19, 1948, 16 U.S.C. 667b–d).

8. Donation of personal property to

public bodies (section 202(h) of the

Federal Property and Administrative

Services Act of 1949, 40 U.S.C. 483(h)).

9. Grants of easements by the General

Services Administration pursuant to the

Act of October 23, 1962, (40 U.S.C. 319–

319(c), and grants by the General

Services Administration of revocable

licenses or permits to use or occupy

Federal real property, if the

consideration to the Government for

such easement, licenses, or permits is

less than estimated fair market value.

10. Conveyance of real property or

interests therein by the General Services

Administration to States or political

subdivisions for street widening

purposes pursuant to the Act of July 7,

1960 (40 U.S.C. 345c), if the

consideration to the Government is less

than estimated fair market value.

11. Allotment of space by the General

Services Administration in Federal

buildings to Federal Credit Unions,

without charge for rent or services

(section 25 of the Federal Credit Union

Act, 12 U.S.C. 1770).

12. Donation of surplus property to

the American National Red Cross

(section 203(l) of the Federal Property

and Administrative Services Act of

1949, 40 U.S.C. 484(l)).

13. Provision by the General Services

Administration of free space and

utilities for vending stands operated by

blind persons (section 1 of the

Randolph-Sheppard Act, 20 U.S.C. 107).

14. Donation of forfeited distilled

spirits, wine, and malt beverages to

eleemosynary institutions (26 U.S.C.

5688).

15. Donation of surplus Federal

records (Federal Records Disposal Act of

1943, 44 U.S.C. 366–380).

16. Grants to State and local agencies

and to nonprofit organizations and

institutions for the collecting,

describing, preserving and compiling,

and publishing of documentary sources

significant to the history of the United

States (section 503 of the Federal

Property and Administrative Services

Act of 1949, as amended by Public Law

88–383).

17. Loan of machine tools and

industrial manufacturing equipment in

the national industrial reserve to

nonprofit educational institutions or

training schools (section 7 of the

National Industrial Reserve Act of 1948,

50 U.S.C. 456).

18. District of Columbia grant-in-aid

hospital program (60 Stat. 896, as

amended).

19. Disposal of surplus real property

for use in the provision of rental or

cooperative housing to be occupied by

families or individuals of low or

moderate income (section 414 of the

Housing and Urban Development Act of

1969, Public Law 91–152).

20. Payments in lieu of taxes on

certain real property transferred from

the Reconstruction Finance Corporation

(Title VII of the Federal Property and

Administrative Services Act of 1949, 40

U.S.C. 521–524).

21. Conveyance of certain lands and

property to the State of Hawaii without

reimbursement (Pub. L. 88–233, 77 Stat.

472).

Dated: November 21, 2000.

James M. Taylor,

Acting Associate Administrator, Office of

Civil Rights, General Services Administration.

[FR Doc. 00–30213 Filed 11–27–00; 8:45 am]

BILLING CODE 6820–34–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

White House Commission on

Complementary and Alternative

Medicine Policy; Notice of Meeting

Pursuant to Section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is given of a meeting of the White House

Commission on Complementary and

Alternative Medicine Policy.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The purpose of the meeting is to

convene the Commission to receive

testimony from invited speakers and

organizations interested in the subject of

federal policy regarding complementary

and alternative medicine. The major

focus of the meeting is on the access to

and delivery of complementary and

alternative (CAM) services: Use,

effectiveness, and delivery systems.

Comments received at the meeting may

be used by the Commission to prepare

the Report to the President as required

by the Executive Order.

Comments should focus on the Access

and Delivery of Complementary and

Alternative Medicine Services: Use,

Effectiveness, and Delivery Systems.

Issues to be discussed include the

following: Utilization of CAM Services;

Access and Delivery of CAM Services;

Issues in Integrating the Delivery of

CAM Services; Patient Perspectives on

the Use of CAM Services; Meeting

Public Needs—Public and Private

Sectors Delivery Systems; and Novel

Systems of CAM Services Delivery.

Discussion also may focus on the

following questions:

(1) Do patients and health care

providers have ready access to CAM

practices and interventions?

(2) How can access to safe and

effective CAM practices and

interventions be improved?

Name of Committee: The White

House Commission on Complementary

and Alternative Medicine Policy.

Date: December 4–5, 2000.

Time: December 4—9:15 a.m.–6:00

p.m.; December 5—8:00 a.m.–4:00 p.m.

Place: Hubert H. Humphrey Building,

Room 800, 200 Independence Avenue,

S.W., Washington, D.C. 20201.

Contact Persons: Michele M. Chang,

CMT, MPH, Executive Secretary, or

Federal Register / Vol. 65, No. 229 / Tuesday, November 28, 2000 / Notices 70915

Stephen C. Groft, Pharm.D., Executive

Director, 6701 Rockledge Drive, Room

1010, MSC 7707, Bethesda, MD 20817–

7707, Phone: (301) 435–7592, Fax: (301)

480–1691, E-mail:

WHCCAMP@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The

President established the White House

Commission on Complementary and

Alternative Medicine Policy on March

7, 2000, by Executive Order 13147. The

mission of the White House

Commission on Complementary and

Alternative Medicine Policy is to

provide a report, through the Secretary

of the Department of Health and Human

Services, on legislative and

administrative recommendations for

assuring that public policy maximizes

the benefits of complementary and

alternative medicine to Americans.

Public Participation

Oral statements by the public will be

provided on December 4, from about

1:30 p.m.–2:30 p.m. (Time

approximate). Members of the public

who wish to present oral comment may

register by calling 1–800–953–3298 or

by accessing https://safe2.sba.com/

whccamp/index.cfm or the website of

the Commission at http://

whccamp.hhs.gov no later than

November 27, 2000.

Oral comments will be limited to five

minutes; three minutes of oral

presentation and two minutes to

respond to questions by Commission

members. Individuals who register to

speak will be assigned in the order in

which they registered. Due to time

constraints, only one representative

from each organization will be allotted

time for oral testimony. The number of

speakers and the time allotted may also

be limited by the number of registrants.

All requests to register should include

the name, address, telephone number,

and business or professional affiliation

of the interested party, and should

indicate the area of interest or question

(as described above) to be addressed.

When mailing or faxing written

comments provide, if possible, an

electronic version on diskette.

Any person attending the meeting

who has not registered to speak in

advance of the meeting will be allowed

to make a brief oral statement during the

time set aside for public comment if

time permits, and at the chairperson’s

discretion. Individuals unable to attend

the meeting, or any interested parties,

may send written comments by mail,

fax, or electronically to the staff office

of the Commission for inclusion in the

public record.

Because of the need to obtain the

views of the public on these issues as

soon as possible and because of the

early deadline for the report required of

the Commission, this notice is being

provided at the earliest possible time.

Dated: November 17, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–30175 Filed 11–27–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

and the Assistant Secretary for Health

have taken final action in the following

case:

Evan B. Dreyer, M.D., Ph.D.,

Massachusetts Eye and Ear Infirmary

(MEEI) and Harvard Medical School

(HMS): Based on the findings and

evidence documented in a report by a

joint inquiry panel, dated November 17,

1997, and additional information

obtained by the Office of Research

Integrity (ORI) during its oversight

review, on April 14, 2000, PHS issued

its findings that Dr. Dreyer, former HMS

Associate Professor of Ophthalmology at

MEEI, engaged in scientific misconduct

by falsifying or fabricating experimental

results. These results were included in

National Institute on Deafness and

Other Communication Disorders

(NIDCD), National Institutes of Health

(NIH), grant application K08 DC00131–

01A1.

Specifically, Dr. Dreyer falsified or

fabricated experimental results to

support the hypothesis that elevated

levels of the amino acid glutamate play

a role in Meniere’s disease and reported

these falsified or fabricated results in six

documents:

1. An NIH grant application, K08

DC0013 l–0lA1, ‘‘Glutamate toxicity in

endolymphatic hydrops,’’ submitted to

NIH for a Mentored Clinical Scientist

Development Award in July 1996. PHS

found that the experimental results for

19 amino acids reported in Table 2 and

the text (pp. 58–59) were falsified or

fabricated.

2. An abstract, Cliff A. Megerian,

M.D., Michael J. McKenna, M.D., Joseph

B. Nadol, Jr., M.D., and Evan B. Dreyer,

M.D., Ph.D. ‘‘Elevated Perilymphatic

Glutamate and Type-1 Spiral Ganglion

Cell Loss in the Hydropic Ear,’’

submitted on August 1, 1996, for the

Triological Society Eastern Division

Meeting scheduled for early February

1997. PHS found that the text reports

the same falsified or fabricated

experimental results for the amino acid

glutamate that were reported in the K08

DC00131–OlA1 grant application to

support the conclusion that elevated

levels of glutamate may play a role in

Meniere’s disease.

3. A manuscript, Cliff A. Megerian,

M.D., Michael J. McKenna, M.D., Joseph

B. Nadol, Jr., M.D., Barbara J. Burgess,

B.A., David Zurakowski, Ph.D., and

Evan B. Dreyer, M..D., Ph.D. ‘‘Elevated

Perilymphatic Glutamate and Type-1

Spiral Ganglion Cell Loss in the

Hydropic Ear.’’ PHS found that Table 1

and the text (pp. 2 and 8) contained the

same falsified or fabricated

experimental results that were reported

in the K08 DC00131–OlA1 grant

application.

4. A draft NIH grant application,

listing Dr. Dreyer as Principal

Investigator, in which Table 2 and the

text of the draft NIH grant application

contained the same experimental results

that the PHS found were falsified or

fabricated in K08 DC00131-OlA1.

5. Two computer spreadsheets, which

contained the same results that the PHS

found were falsified or fabricated in the

K08 DC00131-OlA1.

6. Magneto-optical computer disk,

which contained files with 21 fabricated

chromatograms of amino acid elution

patterns. On January 21, 1997, Dr.

Dreyer provided the computer disk to

MEEI officials in response to requests

for the primary data and laboratory

notebooks supporting the amino acid

results reported in the documents

described above. On April 7 and May

21, 1997, Dr. Dreyer admitted that he

fabricated each of the 21

chromatograms.

On May 10, 2000, Dr. Dreyer appealed

the proposed PHS findings and

administrative actions to the HHS

Departmental Appeals Board (‘‘DAB’’),

DAB Docket No. A–2000–72. However,

on November 13, 2000, Dr. Dreyer

entered into a Voluntary Exclusion

Agreement (Agreement) with PHS in

which he agreed to withdraw his appeal

of the PHS findings of scientific

misconduct against him.

Under the terms of the Agreement,

with respect to the items in Paragraphs

1–5, Dr. Dreyer did not admit that he

falsified or fabricated the results at

issue, but he recognized that if the DAB

case proceeded to conclusion, there was

sufficient evidence upon which the

DAB may make a finding of scientific